Your browser doesn't support javascript.
loading
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
Wylie, Andrew A; Schoepfer, Joseph; Jahnke, Wolfgang; Cowan-Jacob, Sandra W; Loo, Alice; Furet, Pascal; Marzinzik, Andreas L; Pelle, Xavier; Donovan, Jerry; Zhu, Wenjing; Buonamici, Silvia; Hassan, A Quamrul; Lombardo, Franco; Iyer, Varsha; Palmer, Michael; Berellini, Giuliano; Dodd, Stephanie; Thohan, Sanjeev; Bitter, Hans; Branford, Susan; Ross, David M; Hughes, Timothy P; Petruzzelli, Lilli; Vanasse, K Gary; Warmuth, Markus; Hofmann, Francesco; Keen, Nicholas J; Sellers, William R.
Afiliação
  • Wylie AA; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.
  • Schoepfer J; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Jahnke W; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Cowan-Jacob SW; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Loo A; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.
  • Furet P; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Marzinzik AL; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Pelle X; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Donovan J; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.
  • Zhu W; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.
  • Buonamici S; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.
  • Hassan AQ; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.
  • Lombardo F; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.
  • Iyer V; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Palmer M; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.
  • Berellini G; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.
  • Dodd S; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.
  • Thohan S; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.
  • Bitter H; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.
  • Branford S; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia 5000, Australia.
  • Ross DM; Haematology Directorate, SA Pathology, PO Box 14, Rundle Mall, Adelaide, South Australia 5000, Australia.
  • Hughes TP; South Australian Health &Medical Research Institute (SAHMRI), North Terrace, Adelaide, South Australia 5000, Australia.
  • Petruzzelli L; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.
  • Vanasse KG; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.
  • Warmuth M; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.
  • Hofmann F; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Keen NJ; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.
  • Sellers WR; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.
Nature ; 543(7647): 733-737, 2017 03 30.
Article em En | MEDLINE | ID: mdl-28329763
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Leucemia Mielogênica Crônica BCR-ABL Positiva / Proteínas de Fusão bcr-abl / Niacinamida / Sítio Alostérico Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Leucemia Mielogênica Crônica BCR-ABL Positiva / Proteínas de Fusão bcr-abl / Niacinamida / Sítio Alostérico Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article